RUNX1 isoform imbalance drives ML-DS, VWF-binding RNA aptamer for hemophilia A treatment, and EZH1/2 inhibitor valemetostat in relapsed/refractory ATL
Blood Podcast
00:00
Introduction
An imbalance among Runk's 1 isoforms is key to the pathogenesis of trisomy-21-associated myeloid leukemia. Up next, an RNA aptomer demonstrates promising results in patients with hemophilia A. Phase II data on Valometostat, a selective inhibitor of EZH1 and II in relapsed or refractory adult T-cell leukemia lymphoma.
Transcript
Play full episode
